<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02040792</url>
  </required_header>
  <id_info>
    <org_study_id>0117</org_study_id>
    <nct_id>NCT02040792</nct_id>
  </id_info>
  <brief_title>A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Phase 2B, 28-Day, Randomized, Double-Blind Placebo-Controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma R &amp; D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma R &amp; D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated the safety and efficacy of four doses of TD-4208 and a placebo product
      when administered once daily for 28 days using a jet nebulizer to patients with moderate to
      severe chronic obstructive pulmonary disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Trough FEV1 (Forced Expiratory Volume in One Second)</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">355</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>44 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD-4208</description>
  </arm_group>
  <arm_group>
    <arm_group_label>88 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD-4208</description>
  </arm_group>
  <arm_group>
    <arm_group_label>175 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD-4208</description>
  </arm_group>
  <arm_group>
    <arm_group_label>350 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD-4208</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-4208</intervention_name>
    <arm_group_label>44 mcg</arm_group_label>
    <arm_group_label>88 mcg</arm_group_label>
    <arm_group_label>175 mcg</arm_group_label>
    <arm_group_label>350 mcg</arm_group_label>
    <other_name>revefenacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a male or female subject 40 years of age or older

          -  Subject must have a negative pregnancy test, and must be prepared to use effective
             contraception if of child-bearing potential

          -  Subject is capable of performing reproducible spirometry maneuvers

          -  Subject has post-bronchodilator FEV1/FVC ratio &lt;0.7

          -  Subject has moderate-to-severe stable COPD (Stage 2 or 3 according to the GOLD
             Guidelines)

          -  Subject has a post-bronchodilator FEV1 greater than or equal to 30% and less than 80%
             of predicted normal

          -  Subject has a current or past smoking history of at least 10 pack-years.

        Exclusion Criteria:

          -  Subject has a significant respiratory disease or disorder other than COPD that would
             affect the interpretation of data from this study

          -  Subject has a history of reactions or hypersensitivity to inhaled or nebulized
             anticholinergic or beta-agonist agents

          -  Subject suffers from any medical condition that would preclude the use of inhaled
             anticholinergic agents

          -  Subject has been hospitalized for COPD or pneumonia within 12 weeks

          -  Subject requires long-term oxygen therapy (&gt;15 hours a day)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn Crater</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma, US, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Upstate Pharmaceutical Research</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2014</study_first_submitted>
  <study_first_submitted_qc>January 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2014</study_first_posted>
  <results_first_submitted>June 30, 2016</results_first_submitted>
  <results_first_submitted_qc>October 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 7, 2016</results_first_posted>
  <last_update_submitted>July 17, 2017</last_update_submitted>
  <last_update_submitted_qc>July 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One subject who received placebo was excluded from the efficacy analysis. The reason for this is that the subject was found to be participating in a GSK (GlaxoSmithKline) study with another investigational agent at the same time as their participation in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo
Placebo</description>
        </group>
        <group group_id="P2">
          <title>44 mcg</title>
          <description>TD-4208
TD-4208</description>
        </group>
        <group group_id="P3">
          <title>88 mcg</title>
          <description>TD-4208
TD-4208</description>
        </group>
        <group group_id="P4">
          <title>175 mcg</title>
          <description>TD-4208
TD-4208</description>
        </group>
        <group group_id="P5">
          <title>350 mcg</title>
          <description>TD-4208
TD-4208</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="71"/>
                <participants group_id="P5" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="64"/>
                <participants group_id="P5" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo
Placebo</description>
        </group>
        <group group_id="B2">
          <title>44 mcg</title>
          <description>TD-4208
TD-4208</description>
        </group>
        <group group_id="B3">
          <title>88 mcg</title>
          <description>TD-4208
TD-4208</description>
        </group>
        <group group_id="B4">
          <title>175 mcg</title>
          <description>TD-4208
TD-4208</description>
        </group>
        <group group_id="B5">
          <title>350 mcg</title>
          <description>TD-4208
TD-4208</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="71"/>
            <count group_id="B4" value="71"/>
            <count group_id="B5" value="74"/>
            <count group_id="B6" value="354"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="9.17"/>
                    <measurement group_id="B2" value="60.9" spread="8.87"/>
                    <measurement group_id="B3" value="60.4" spread="7.98"/>
                    <measurement group_id="B4" value="64.5" spread="7.69"/>
                    <measurement group_id="B5" value="61.4" spread="8.98"/>
                    <measurement group_id="B6" value="61.9" spread="8.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="176"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="40"/>
                    <measurement group_id="B6" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Trough FEV1 (Forced Expiratory Volume in One Second)</title>
        <time_frame>Baseline to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
          <group group_id="O2">
            <title>44 mcg</title>
            <description>TD-4208
TD-4208</description>
          </group>
          <group group_id="O3">
            <title>88 mcg</title>
            <description>TD-4208
TD-4208</description>
          </group>
          <group group_id="O4">
            <title>175 mcg</title>
            <description>TD-4208
TD-4208</description>
          </group>
          <group group_id="O5">
            <title>350 mcg</title>
            <description>TD-4208
TD-4208</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough FEV1 (Forced Expiratory Volume in One Second)</title>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.4" spread="25.36"/>
                    <measurement group_id="O2" value="19.4" spread="24.98"/>
                    <measurement group_id="O3" value="155.0" spread="24.61"/>
                    <measurement group_id="O4" value="134.2" spread="25.07"/>
                    <measurement group_id="O5" value="138.2" spread="24.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>One subject who received placebo was excluded from the efficacy analysis. The reason for this is that the subject was found to be participating in a GSK study with another investigational agent at the same time as their participation in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo
Placebo</description>
        </group>
        <group group_id="E2">
          <title>44 mcg</title>
          <description>TD-4208
TD-4208</description>
        </group>
        <group group_id="E3">
          <title>88 mcg</title>
          <description>TD-4208
TD-4208</description>
        </group>
        <group group_id="E4">
          <title>175 mcg</title>
          <description>TD-4208
TD-4208</description>
        </group>
        <group group_id="E5">
          <title>350 mcg</title>
          <description>TD-4208
TD-4208</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI may communicate the trial results generated by the PI, but only after the first publication or presentation of the combined study results generated by all participating sites. The Sponsor can then review trial results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The Sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Glenn Crater, Head of Clinical Development &amp; Medical Affairs, Respiratory</name_or_title>
      <organization>Theravance Biopharma US, Inc.</organization>
      <phone>650-808-6000</phone>
      <email>gcrater@theravance.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

